Reg. No : 2309101564 Name : ARCHANA KUMARI Reg. Date : 27-Sep-2023 Collected On : 27-Sep-2023 10:11

Age/Sex : 27 Years / Female

Approved On : 27-Sep-2023 11:08 **Printed On** : 20-Oct-2023 13:16

Ref. By

Client

: MEDIWHEEL WELLNESS

| <u>Parameter</u> | Result | <u>Unit</u> | Reference Interval |
|-------------------------------------|------------|-------------|--------------------|
| COMPLETE BLOOD COUNT (CBC) | | | |
| | SPECIMEN | EDTA BLOOD | |
| Hemoglobin | 10.3 | g/dL | 12.0 - 15.0 |
| RBC Count | 4.42 | million/cmm | 3.8 - 4.8 |
| Hematrocrit (PCV) | 33.8 | % | 40 - 54 |
| MCH | 23.3 | Pg | 27 - 32 |
| MCV | 76.5 | fL | 83 - 101 |
| MCHC | 30.5 | % | 31.5 - 34.5 |
| RDW | 15.3 | % | 11.5 - 14.5 |
| WBC Count | 7170 | /cmm | 4000 - 11000 |
| DIFFERENTIAL WBC COUNT (Flow | cytometry) | | |
| Neutrophils (%) | 56 | % | 38 - 70 |
| Lymphocytes (%) | 38 | % | 20 - 40 |
| Monocytes (%) | 04 | % | 2 - 8 |
| Eosinophils (%) | 02 | % | 0 - 6 |
| Basophils (%) | 00 | % | 0 - 2 |
| Neutrophils | 4015 | /cmm | |
| Lymphocytes | 2725 | /cmm | |
| Monocytes | 287 | /cmm | |
| Eosinophils | 143 | /cmm | |
| Basophils | 0 | /cmm | |
| Platelet Count (Flow cytometry) | 184000 | /cmm | 150000 - 450000 |
| MPV | 11.9 | fL | 7.5 - 11.5 |
| ERYTHROCYTE SEDIMENTATION RATE | | | |
| ESR (After 1 hour) | 11 | mm/hr | 0 - 21 |
| Modified Westergren Method | | | |
| | | | |

----- End Of Report -----

Page 1 of 10



: 2309101564 Reg. No

Name : ARCHANA KUMARI Age/Sex : 27 Years / Female

Approved On : 27-Sep-2023 11:13

Reg. Date

Collected On

Ref. By

Client

: MEDIWHEEL WELLNESS

Printed On : 20-Oct-2023 13:16

: 27-Sep-2023

: 27-Sep-2023 10:11

<u>Unit</u> **Reference Interval Parameter** Result

PLASMA GLUCOSE

Fasting Blood Sugar (FBS) 85.9 mg/dL 70 - 110

Hexokinase Method

Criteria for the diagnosis of diabetes1. HbA1c >/= 6.5 *

Or 2. Fasting plasma glucose >126 gm/dL. Fasting is defined as no caloric intake at least for 8 hrs.

Or

3. Two hour plasma glucose >/= 200mg/dL during an oral glucose tolerence test by using a glucose load containing equivalent of 75 gm anhydrous glucose dissolved in water. Or

4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose >/= 200 mg/dL. *In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing.

American diabetes association. Standards of medical care in diabetes 2011. Diabetes care 2011;34;S11.

----- End Of Report -----

Page 2 of 10

Approved by: DR PS RAO MD Pathologist

TEST REPORT

: 2309101564 Reg. No

Name : ARCHANA KUMARI Age/Sex : 27 Years / Female

Reg. Date

: 27-Sep-2023 Collected On : 27-Sep-2023 10:11

Approved On : 27-Sep-2023 11:13

Ref. By Client

: MEDIWHEEL WELLNESS

Printed On : 20-Oct-2023 13:16

| <u>Parameter</u> | <u>Result</u> | <u>Unit</u> | Reference Interval | |
|--|---------------|---------------|--------------------|--|
| | VIDNEY EI | JNCTION TEST | | |
| | KIDNET FO | DINCTION 1EST | | |
| UREA (Urease & glutamate dehydrogenase) | 25.9 | mg/dL | 10 - 50 | |
| Creatinine (Jaffe method) | 0.67 | mg/dL | 0.5 - 1.2 | |
| Uric Acid (Enzymatic colorimetric) | 2.5 | mg/dL | 2.5 - 7.0 | |
| | | | | |

----- End Of Report -----



Reg. No : 2309101564

Name : ARCHANA KUMARI
Age/Sex : 27 Years / Female

Ref. By

Client : MEDIWHEEL WELLNESS

Reg. Date : 27-Sep-2023

Collected On : 27-Sep-2023 10:11

Approved On : 27-Sep-2023 11:13

Printed On : 20-Oct-2023 13:16

| <u>Parameter</u> | Result | <u>Unit</u> | Reference Interval |
|------------------------------------|--------|-------------|--------------------|
| LIVER FUNCTION TEST WITH GGT | | | |
| Total Bilirubin | 0.56 | mg/dL | 0.20 - 1.0 |
| Colorimetric diazo method | | | |
| Conjugated Bilirubin | 0.25 | mg/dL | 0.0 - 0.3 |
| Sulph acid dpl/caff-benz | | | |
| Unconjugated Bilirubin | 0.31 | mg/dL | 0.0 - 1.1 |
| Sulph acid dpl/caff-benz | | | |
| SGOT | 19.1 | U/L | 0 - 31 |
| (Enzymatic) | | | |
| SGPT | 13.3 | U/L | 0 - 31 |
| (Enzymatic) | | | |
| GGT | 10.2 | U/L | 7 - 32 |
| (Enzymatic colorimetric) | | | |
| Alakaline Phosphatase | 121.1 | U/L | 42 - 141 |
| (Colorimetric standardized method) | | | |
| Protien with ratio | | | |
| Total Protein | 7.7 | g/dL | 6.5 - 8.7 |
| (Colorimetric standardized method) | | | |
| Albumin | 5.0 | mg/dL | 3.5 - 4.94 |
| (Colorimetric standardized method) | | | |
| Globulin | 2.70 | g/dL | 2.3 - 3.5 |
| Calculated | | | |
| A/G Ratio | 1.85 | | 0.8 - 2.0 |
| Calculated | | | |
| | | | |
| | | | |

----- End Of Report -----



Reg. No : 2309101564

Name : ARCHANA KUMARI : 27 Years / Female Age/Sex

Ref. By

Client : MEDIWHEEL WELLNESS Reg. Date : 27-Sep-2023

Collected On : 27-Sep-2023 10:11 **Approved On** : 27-Sep-2023 11:13

Printed On : 20-Oct-2023 13:16

| <u>Parameter</u> | <u>Result</u> | <u>Unit</u> | Reference Interval | |
|---|---------------|-------------|--|--|
| LIPID PROFILE | | | | |
| Cholesterol (Enzymatic colorimetric) | 137.0 | mg/dL | Desirable : < 200.0 Borderline High : 200-239 High : > 240.0 | |
| Triglyceride (Enzymatic colorimetric) | 70.6 | mg/dL | Normal : < 150.0 Borderline : 150-199 High : 200-499 Very High : > 500.0 | |
| VLDL | 14.12 | mg/dL | 15 - 35 | |
| Calculated | | | | |
| LDL CHOLESTEROL | 90.38 | mg/dL | Optimal : < 100.0 Near / above optimal : 100-129 Borderline High : 130-159 High : 160-189 Very High : >190.0 | |
| HDL Cholesterol Homogeneous enzymatic colorin | 32.5 | mg/dL | 30 - 85 | |
| Cholesterol /HDL Ratio Calculated | 4.22 | | 0 - 5.0 | |
| LDL / HDL RATIO Calculated | 2.78 | | 0 - 3.5 | |

This is an electronically authenticated report.



2309101564 Reg. No

Name ARCHANA KUMARI Age/Sex 27 Years / Female

Ref. By

Client MEDIWHEEL WELLNESS Reg. Date : 27-Sep-2023

Collected On : 27-Sep-2023 10:11 Approved On : 27-Sep-2023 11:13

Printed On : 20-Oct-2023 13:16

Parameter Result <u>Unit</u> Reference Interval

NEW ATP III GUIDELINES (MAY 2001), MODIFICATION OF NCEP<?xml:namespace prefix = "o" ns = "urn:schemasmicrosoft-com:office:office" />

> LDL CHOLESTEROL **CHOLESTEROL HDL CHOLESTEROL TRIGLYCERIDES**

Optimal<100 Desirable<200 Low<40 Normal<150 Near Optimal 100-129 Border Line 200-239 High >60 Border High 150-199 Borderline 130-159 High >240 High 200-499 High 160-189

- LDL Cholesterol level is primary goal for treatment and varies with risk category and assessment
- For LDL Cholesterol level Please consider direct LDL value

Risk assessment from HDL and Triglyceride has been revised. Also LDL goals have changed.

- Detail test interpreation available from the lab
- All tests are done according to NCEP guidelines and with FDA approved kits.
- LDL Cholesterol level is primary goal for treatment and varies with risk category and assesment

For test performed on specimens received or collected from non-KSHIPRA locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender.

KSHIPRA will be responsible Only for the analytical part of test carried out. All other responsibility will be of referring Laboratory.

. All other responsibility will be of referring Laboratory.

----- End Of Report -----

Page 6 of 10

DR PS RAO

MD Pathologist

This is an electronically authenticated report.

Reg. No : 2309101564

Name : ARCHANA KUMARI
Age/Sex : 27 Years / Female

Collected On : 27-Sep-2023 10:11 **Approved On** : 27-Sep-2023 11:13

: 27-Sep-2023

Reg. Date

Ref. By

Client : MEDIWHEEL WELLNESS

Printed On : 20-Oct-2023 13:16

| <u>Parameter</u> | <u>Result</u> | <u>Unit</u> | Reference Interval | |
|-------------------------|---------------|-------------|--------------------|--|
| THYROID FUNCTION TEST | | | | |
| T3 (Triiodothyronine) | 0.98 | ng/mL | 0.87 - 1.78 | |
| Chemiluminescence | | | | |
| T4 (Thyroxine) | 8.79 | μg/dL | 5.89 - 14.9 | |
| Chemiluminescence | | | | |
| TSH (ultra sensitive) | 3.368 | μIU/ml | 0.34 - 5.6 | |
| Chemiluminescence | | | | |

SUMMARY The hypophyseal release of TSH (thyrotropic hormone) is the central regulating mechanism for the biological action of thyroid hormones. TSH is a very sensitive and specific parameter for assessing thyroid function and is particularly suitable for early detection or exclusion of disorders in the central regulating circuit between the hypothalamus, pituitary and thyroid. LIMITATION Presence of autoantibodies may cause unexpected high value of TSH

----- End Of Report -----

This is an electronically authenticated report.

TEST REPORT

: 2309101564 Reg. No : ARCHANA KUMARI Name Age/Sex 27 Years / Female

Collected On

Reg. Date

: 27-Sep-2023 : 27-Sep-2023 10:11

Approved On

: 27-Sep-2023 11:13

Ref. By

Printed On

Reference Interval

: 20-Oct-2023 13:16

Client : MEDIWHEEL WELLNESS

Parameter

Unit

HEMOGLOBIN A1 C ESTIMATION

Specimen: Blood EDTA

Hb A1C

5.9

Result

% of Total Hb

Poor Control: > 7.0 % Good Control: 6.2-7.0 %

Boronate Affinity with Fluorescent Quenching

Non-diabetic Level: 4.3-6.2 %

Mean Blood Glucose Calculated

132.74

mg/dL

Degree of Glucose Control Normal Range:

Poor Control >7.0% *

Good Control 6.0 - 7.0 %**Non-diabetic level < 6.0 %

- * High risk of developing long term complication such as retinopathy, nephropathy, neuropathy, cardiopathy, etc.
- * Some danger of hypoglycemic reaction in Type I diabetics.
- * Some glucose intolerant individuals and "subclinical" diabetics may demonstrate HbA1c levels in this area.

EXPLANATION:-

Total haemoglobin A1 c is continuously symthesised in the red blood cell throught its 120 days life span. The concentration of HBA1c in the cell reflects the average blood glucose concentration it encounters.

*The level of HBA1c increases proportionately in patients with uncontrolled diabetes. It reflects the average blood glucose oncentration over an extended time period and remains unaffected by short-term fluctuations in blood glucose levels.

*The measurement of HbA1c can serve as a convenient test for evaluating the adequacy of diabetic control and in preventing various diabetic complications. Because the average half life of a red blood cell is sixty days. HbA1c has been accepted as a measurnment which eflects the mean daily blood glucose concentration, better than fasting blood glucose determination, and the degree of carbohydrate imbalance over the preceding two months.

*It may also provide a better index of control of the diabetic patient without resorting to glucose loading procedures.

HbA1c assay Interferences:

*Errneous values might be obtained from samples with abnormally elevated quantities of other Haemoglobins as a result of either their simultaneous elution with HbA1c(HbF) or differences in their glycation from that of HbA(HbS)

----- End Of Report -----

Page 8 of 10

This is an electronically authenticated report.

DR PS RAO Approved by: MD Pathologist

Test done from collected sample

TEST REPORT

Reg. No : 2309101564 Name : ARCHANA KUMARI Age/Sex

Collected On : 27-Sep-2023 10:11 **Approved On** : 27-Sep-2023 11:25

: 27-Sep-2023

Ref. By

: 27 Years / Female

Printed On : 20-Oct-2023 13:16

Parameter

Reg. Date

Client : MEDIWHEEL WELLNESS

> Result <u>Unit</u> Reference Interval

URINE ROUTINE EXAMINATION

PHYSICAL EXAMINATION

Quantity 20 cc

Pale Yellow Colour

Clear **Appearance**

CHEMICAL EXAMINATION (BY REFLECTANCE PHOTOMETRIC METHOD)

рΗ 7.0 5.0 - 8.01.015 1.002 - 1.03 Sp. Gravity

Protein Nil Nil Glucose Ketone Bodies Nil Urine Bile salt and Bile Pigment Nil Urine Bilirubin Nil **Nitrite** Nil Leucocytes Trace Blood Trace

MICROSCOPIC EXAMINATION (MANUAL BY MCIROSCOPY)

Leucocytes (Pus Cells) 8 - 10/hpf Erythrocytes (Red Cells) 4 - 5/hpf **Epithelial Cells** 1-2/hpf **Amorphous Material** Nil Casts Nil Nil Crystals

Bacteria Nil

Monilia Nil

----- End Of Report -----

Page 9 of 10

DR PS RAO Approved by:

MD Pathologist

| | | TEST REPORT | |
|----------|----------------------|--|--|
| Reg. No | : 2309101564 | | Reg. Date : 27-Sep-2023 |
| Name | : ARCHANA KUMARI | | Collected On : 27-Sep-2023 10:11 |
| Age/Sex | : 27 Years / Female | | Approved On : 27-Sep-2023 11:08 |
| Ref. By | : | | Printed On : 20-Oct-2023 13:16 |
| Client | : MEDIWHEEL WELLNESS | | |
| Paramete | <u>er</u> | Result | |
| | Specimen | BLOOD GROUP & RH EDTA and Serum; Method: Haemagglu | ıtination |
| ABO | | 'B' | |
| Rh (D) | | Positive | |
| | | End Of Report | |